MedTrace Logo

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT06193889 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-05-15

No results posted yet for this study

Summary

A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis

Conditions

Interventions

DRUG

Standard of Care Treatment

Standard of Care Medications Optional Crossover to receive KYV-101 treatment

DRUG

Standard lymphodepletion regimen

Standard lymphodepletion regimen

BIOLOGICAL

KYV-101

Anti-CD19 CAR-T cell therapy

Sponsors & Collaborators

  • Kyverna Therapeutics

    lead INDUSTRY

Principal Investigators

  • MD · Kyverna Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-28
Primary Completion
2027-09-30
Completion
2028-09-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06193889 on ClinicalTrials.gov